Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:

- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
546 documents

  • Denis Dauvergne. Online monitoring of ion therapy by prompt gammas. International Symposium on Ion Therapy 2016, Nov 2016, Milan, Italy. ⟨hal-01475266⟩
  • J. Krimmer, L. Balleyguier, D. Dauvergne, M. Fontana, N. Freud, et al.. Absorbed Energy Monitoring during Hadrontherapy via Prompt Gamma Detection. IEEE Nuclear Science Symposium & Medical Imaging Conference (2016 IEEE NSS/MIC), Oct 2016, Strasbourg, France. pp.1-2, ⟨10.1109/NSSMIC.2016.8069621⟩. ⟨hal-01457973⟩
  • M.L. Gallin-Martel, A. Bes, A. BoukhĂ©miri, G. Bosson, J. Collot, et al.. Large Area Polycrystalline Diamond Detectors for Online Hadron Therapy Beam Tagging Applications. IEEE Nuclear Science Symposium & Medical Imaging Conference (2016 IEEE NSS/MIC), Oct 2016, Strasbourg, France. , 2016 IEEE Nuclear Science Symposium, Medical Imaging Conference and Room-Temperature Semiconductor Detector Workshop (NSS/MIC/RTSD), pp.1-5, 2016, Proceedings of the IEEE NSS MIC 2016. ⟨10.1109/NSSMIC.2016.8069398⟩. ⟨hal-01436786⟩
  • Nils Krah, Mauro Testa, Jean Michel LĂ©tang, Simon Rit, Ilaria Rinaldi. An improved computational method to optimize the stopping power calibration curve for patient-specific proton therapy planning. IEEE NSS MIC 2016, Oct 2016, Strasbourg, France. ⟨hal-01492914⟩
  • J-B Guy, B. MĂ©ry, C. Rancoule, A. Vallard, S. Espenel, et al.. Ciblage de la famille HER dans les cancers ORL : efficacitĂ© biologique de l’association de cĂ©tuximab et de pertuzumab combinĂ©e Ă  l’irradiation photonique. 27e Congrès national de la SociĂ©tĂ© française de radiothĂ©rapie oncologique, Oct 2016, Paris, France. pp.742, ⟨10.1016/j.canrad.2016.08.078⟩. ⟨hal-01400259⟩
  • A. Wozny, C. Rancoule, B. MĂ©ry, J-B Guy, A. Gaumier, et al.. Nrf2 et Keap1 : biomarqueurs prĂ©dictifs de radiorĂ©sistance des cancers de la tĂŞte et du cou ?. 27e Congrès national de la SociĂ©tĂ© française de radiothĂ©rapie oncologique, Oct 2016, Paris, France. pp.741-742, ⟨10.1016/j.canrad.2016.08.077⟩. ⟨hal-01400288⟩
  • M Cunha, M Monini, E Testa, M Beuve. NANOX, A MULTI-SCALE MODEL TO PREDICT BIOLOGICAL EFFECTS AND HADRONTHERAPY. International Conference "Dynamics of Systems on the Nanoscale" (DySoN 2016), Oct 2016, Bad Ems, Germany. ⟨hal-01400164⟩
  • R. Delorme, L. Miquel, D. Dauvergne, M. Beuve, C. Monini, et al.. Theoretical approach based on Monte-Carlo simulations to predict the cell survival following BNCT. 17th International Congress on Neutron Capture Therapy (ICNCT-17), Oct 2016, Columbia, United States. . ⟨in2p3-01376064⟩
  • D. Santos, D. Dauvergne, R. Delorme, V. Ghetta, J. Giraud, et al.. Accelerator Based Neutron Capture Therapies in France. 17th International Congress on Neutron Capture Therapy (ICNCT-17), Oct 2016, Columbia, United States. ⟨hal-01481954⟩
  • J-B Guy, B. MĂ©ry, C. Rancoule, A. Vallard, S. Espenel, et al.. HER Family Blockade in Head and Neck Squamous Cell Carcinoma: Couple Therapy Efficacy of Cetuximab and Pertuzumab Combined With Photon Irradiation. 58th Annual Meeting of the American Society for Radiation Oncology, Sep 2016, Boston, United States. pp.E577-E578, ⟨10.1016/j.ijrobp.2016.06.2074⟩. ⟨hal-01400227⟩

Powered by HAL logo